IMPACT OF DEMOGRAPHIC AND IMAGING PARAMETERS OF BASELINE FDG PET/CT UPON OVER-ALL SURVIVAL IN UN-RESECTABLE PANCREATIC DUCT ADENOCARCINOMA TREATED WITH CHEMORADIATION WITH OR WITHOUT IMMUNOTHERAPY
Abstract
Aim/Introduction: Pancreatic duct adenocarcinomas (PDAC) are known to have dismal survival as more than 80% tumors are un-resectable at diagnosis. Chemotherapy with or without radiation is the standard regime in these patients with lower over-all survival (OS). In recent year immunotherapy has been introduced with reported better OS. FDG PET/CT is an effective tool for staging and response evaluation in these patients. Aims of this study were to compare OS in patients with un-resectable PDACs who had chemoradiation with or without immunotherapy and its predictor(s) using demographic and imaging parameters of baseline FDG PET/CT scan.
Methods: This retro-prospective study was conducted at PET/CT Imaging facility of JCIA healthcare facility of Pakistan from (March 2017 till December 2020). Total 29 patients with un-resectable PDACs were included who had FDG PET/CT for staging. Seventeen patients (17/29) received only chemoradiation (CRT-Group) while 12/29 received CRT with immunotherapy (CRT+Im Group). These patients were followed for a median period of 4 months (2-10 months). Kaplan Meier’s survival curves were analyzed to measure OS in both groups. Using Receiver operating characteristics (ROC) curve, demographic and baseline FDG PET/CT parameters were plotted to find out significant predictor(s) of OS in both groups.
Results: Patients with CRT had mean OS 6.9 month (5.3 – 8.5) compared to 8.3 months (6.3 – 10.2) who had CRT+Im (p value > 0.5). Using ROC analysis, age, gender, body mass index (BMI), primary tumor size (PTS) and SUVmax of primary tumor in baseline FDG PET/CT did not show significant impact on OS in either group. However, hypermetabolic bony and pulmonary metastases were found to be significant predictors of shorter OS in both groups (AUC: 0.879 and 0.875 in CRT and CRT+Im respectively; p value <0.05).
Conclusion: In un-resectable PDAC no significant difference in mean OS was found in patients treated with CRT and CRT+Im. Age, gender, BMI, PTS and SUVmax of primary tumor in baseline FDG PET/CT were found non-significant predictors for OS in either group. Hypermetabolic bony and pulmonary metastases on baseline FDG PET/CT were found to be significant predictors of shorter OS in both groups.
Key Words: Pancreatic Duct Adenocarcinoma; FDG PET/CT; Chemoradiationtherapy; Immunotherapy; over-all survival; predictors
Full Text:
PDFReferences
. American Cancer Society. Cancer Facts and Figures 2019. Atlanta: American Cancer Society; 2019
Rahib L, Smith BD, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.
. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg A, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–88.
. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap B , Drapek L, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4:963–69.
. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817–25.
. Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med 2017;377(15):1409–12.
. Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: Barriers and breakthroughs. Ann Gastroenterol Surg 2018;2(4):274–81.
. Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean G, et al. Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) + gemcitabine (gem) in advanced pancreatic cancer (APC). JCO 2019;37(4):298–9
. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013;19(22):6286–95.
. Riquelme, E, Maitra, A, McAllister F. Immunotherapy for Pancreatic Cancer: More than Just a Gut Feeling. Cancer Discov. 2018, 8, 386–88.
. Amin S, Baine M, Meza J, Alam M, Lin C. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Clin Transl Radiat Oncol. 2020;24:34-40. Published 2020 Jun 7. doi:10.1016/j.ctro.2020.06.003
. Henriksen A, Dyhl-Polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev 2019;78:17-30.
. Wainberg ZA, Hochster HS, Kim EJH, George B, Kalyan A, et al. Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC). Clin Cancer Res 2020; 15;26(18):4814-22.
. Chris AG, Megan Q. Survival Analysis of Demographic Factors Associated With 5+ Year Survival of Pancreatic Carcinoma. Cureus 13(1): e13032. doi:10.7759/cureus.13032
. Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surg. 2020;155(2):e195047. doi:10.1001/jamasurg.2019.5047
. Lee S, Reha JL, Tzeng CW, Massarweh NM, Chang GJ, Hetzet SP, al. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol. 2013, 20:4073-79. 10.1245/s10434-013-3130-3
. Hwang JP, Lim I, Chang KJ, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer. Nucl Med Mol Imaging. 2012;46(3):207-14. doi:10.1007/s13139-012-0151-y
Refbacks
- There are currently no refbacks.
© Copyright PJR 2008- |